Credit Suisse Ag Design Therapeutics, Inc. Transaction History

Credit Suisse Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$7.86 - $17.2 $1,501 - $3,285	-191 Reduced 99.48%	1 $0
Q3 2022 Nov 10, 2022	BUY	$14.09 - $25.57 $2,268 - $4,116	161 Added 519.35%	192 $3,000
Q2 2022 Aug 12, 2022	BUY	$9.91 - $17.33 $307 - $537	31 New	31 $0
Q4 2021 Feb 14, 2022	SELL	$13.64 - $21.41 $3.22 Million - $5.05 Million	-235,938 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$13.99 - $20.03 $59,037 - $84,526	-4,220 Reduced 1.76%	235,938 $3.47 Million
Q2 2021 Aug 16, 2021	BUY	$19.02 - $29.78 $3.4 Million - $5.32 Million	178,730 Added 290.96%	240,158 $4.78 Million
Q1 2021 May 14, 2021	BUY	$29.52 - $41.49 $1.81 Million - $2.55 Million	61,428 New	61,428 $1.84 Million

102

31M

2.3K

16.5K

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $347M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.